Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PER1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/PER1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PER1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PER1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PER1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0043409112 | Thyroid | PTC | negative regulation of MAPK cascade | 76/5968 | 180/18723 | 2.15e-03 | 1.14e-02 | 76 |
GO:00709322 | Thyroid | PTC | histone H3 deacetylation | 13/5968 | 20/18723 | 2.37e-03 | 1.24e-02 | 13 |
GO:003314410 | Thyroid | PTC | negative regulation of intracellular steroid hormone receptor signaling pathway | 21/5968 | 38/18723 | 2.38e-03 | 1.25e-02 | 21 |
GO:0051591111 | Thyroid | PTC | response to cAMP | 43/5968 | 93/18723 | 2.59e-03 | 1.33e-02 | 43 |
GO:001657017 | Thyroid | ATC | histone modification | 243/6293 | 463/18723 | 2.23e-17 | 2.27e-15 | 243 |
GO:000641735 | Thyroid | ATC | regulation of translation | 236/6293 | 468/18723 | 2.39e-14 | 1.34e-12 | 236 |
GO:001820516 | Thyroid | ATC | peptidyl-lysine modification | 193/6293 | 376/18723 | 6.92e-13 | 3.06e-11 | 193 |
GO:000647315 | Thyroid | ATC | protein acetylation | 116/6293 | 201/18723 | 1.75e-12 | 7.33e-11 | 116 |
GO:004354315 | Thyroid | ATC | protein acylation | 134/6293 | 243/18723 | 3.46e-12 | 1.40e-10 | 134 |
GO:001839415 | Thyroid | ATC | peptidyl-lysine acetylation | 100/6293 | 169/18723 | 7.65e-12 | 2.91e-10 | 100 |
GO:000647515 | Thyroid | ATC | internal protein amino acid acetylation | 93/6293 | 160/18723 | 1.59e-10 | 4.82e-09 | 93 |
GO:001839315 | Thyroid | ATC | internal peptidyl-lysine acetylation | 92/6293 | 158/18723 | 1.75e-10 | 5.24e-09 | 92 |
GO:001657314 | Thyroid | ATC | histone acetylation | 89/6293 | 152/18723 | 2.31e-10 | 6.72e-09 | 89 |
GO:0048545210 | Thyroid | ATC | response to steroid hormone | 168/6293 | 339/18723 | 7.21e-10 | 1.88e-08 | 168 |
GO:0030522112 | Thyroid | ATC | intracellular receptor signaling pathway | 134/6293 | 265/18723 | 7.58e-09 | 1.63e-07 | 134 |
GO:000931426 | Thyroid | ATC | response to radiation | 210/6293 | 456/18723 | 1.69e-08 | 3.39e-07 | 210 |
GO:004396713 | Thyroid | ATC | histone H4 acetylation | 45/6293 | 67/18723 | 2.01e-08 | 3.93e-07 | 45 |
GO:0043122112 | Thyroid | ATC | regulation of I-kappaB kinase/NF-kappaB signaling | 123/6293 | 249/18723 | 1.65e-07 | 2.64e-06 | 123 |
GO:0007249111 | Thyroid | ATC | I-kappaB kinase/NF-kappaB signaling | 135/6293 | 281/18723 | 3.31e-07 | 4.91e-06 | 135 |
GO:007138328 | Thyroid | ATC | cellular response to steroid hormone stimulus | 103/6293 | 204/18723 | 4.32e-07 | 6.30e-06 | 103 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PER1 | SNV | Missense_Mutation | | c.359N>T | p.Ser120Phe | p.S120F | O15534 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
PER1 | SNV | Missense_Mutation | | c.3206N>G | p.Ser1069Cys | p.S1069C | O15534 | protein_coding | tolerated(0.06) | possibly_damaging(0.88) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PER1 | SNV | Missense_Mutation | | c.1120N>C | p.Asp374His | p.D374H | O15534 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PER1 | SNV | Missense_Mutation | novel | c.2927N>T | p.Ser976Leu | p.S976L | O15534 | protein_coding | deleterious(0) | possibly_damaging(0.606) | TCGA-AC-A3BB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | CR |
PER1 | SNV | Missense_Mutation | novel | c.1478N>C | p.Ile493Thr | p.I493T | O15534 | protein_coding | deleterious(0) | probably_damaging(0.921) | TCGA-AR-A0TT-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
PER1 | SNV | Missense_Mutation | novel | c.633G>T | p.Glu211Asp | p.E211D | O15534 | protein_coding | deleterious(0.01) | probably_damaging(0.952) | TCGA-B6-A3ZX-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD |
PER1 | SNV | Missense_Mutation | | c.2852N>T | p.Ser951Leu | p.S951L | O15534 | protein_coding | tolerated(0.16) | benign(0.003) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PER1 | SNV | Missense_Mutation | | c.2570N>T | p.Ser857Leu | p.S857L | O15534 | protein_coding | tolerated(0.23) | benign(0) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PER1 | SNV | Missense_Mutation | | c.386N>T | p.Ser129Leu | p.S129L | O15534 | protein_coding | deleterious(0) | probably_damaging(0.942) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PER1 | SNV | Missense_Mutation | rs535351039 | c.1264C>T | p.His422Tyr | p.H422Y | O15534 | protein_coding | tolerated(0.62) | probably_damaging(0.968) | TCGA-D8-A1JF-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |